SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject1/12/2004 7:19:18 AM
From: nigel bates  Read Replies (1) of 625
 
Cambridge Antibody Technology: Clinical Trials Update
Monday January 12, 7:02 am ET

CAMBRIDGE, England, Jan. 12 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology Group plc (LSE: CAT - News; Nasdaq: CATG - News) today announces the completion of enrolment in the Phase III pivotal International clinical trial of Trabio(TM), a human anti-TGF beta monoclonal antibody, in patients undergoing first time surgery for glaucoma (trabeculectomy). A total of 393 patients in six European countries and South Africa were randomised in the double-blind trial which compares Trabio with placebo. Data from this trial are expected in early 2005 when all patients will have completed at least one year of follow- up post surgery.

CAT also reports the announcement by its licensee Human Genome Sciences, Inc., (Nasdaq: HGSI - News) that it has begun dosing patients in a Phase II clinical trial of LymphoStat-B(TM), a human monoclonal antibody which modulates the activities of B-lymphocytes, for the treatment of rheumatoid arthritis. The double-blind, placebo-controlled multi-centre Phase II trial will evaluate safety, optimal dosing and efficacy of LymphoStat-B in approximately 230 patients with active rheumatoid arthritis who have failed prior therapy...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News